Skip to main content
logo
Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.19
+0.23 (0.72%)
Oct 19, 2026, 2:52 PM EDT - Market open

Castle Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
357.28344.23332.07219.79137.0494.09
Revenue Growth
3.18%3.66%51.09%60.38%45.65%50.18%
Gross Profit
276.03273.2271.86174.81105.0378.26
Operating Income
-12.01-22.718.67-67.98-91.14-40.08
Net Income
-19.42-24.1618.25-57.47-67.14-31.29
Earnings Per Share
-0.65-0.830.62-2.14-2.58-1.24
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
266.81299.51293.13243.1258.63329.63
Total Debt
36.6537.0226.4515.4113.558.31
Net Cash (Debt)
230.16262.49266.69227.69245.08321.33
Net Cash Growth
-3.53%-1.57%17.13%-7.09%-23.73%-21.60%
Net Cash Per Share
7.759.069.128.509.4112.78

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
42.6364.3564.87-5.63-41.66-18.98
Capital Expenditures
-43.12-36.02-28.33-13.62-5.63-3.48
Free Cash Flow
-0.4928.3336.54-19.25-47.29-22.47
Free Cash Flow Growth
--22.48%----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
77.26%79.37%81.87%79.53%76.64%83.18%
Operating Margin
-3.36%-6.60%2.61%-30.93%-66.51%-42.60%
Pretax Margin
-5.37%-8.57%6.49%-26.10%-50.28%-42.53%
Profit Margin
-5.43%-7.02%5.49%-26.15%-48.99%-33.26%
FCF Margin
-0.14%8.23%11.00%-8.76%-34.51%-23.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--40.91---
P/FCF Ratio
-40.0920.43---
PS Ratio
2.753.302.252.644.5311.72